The invention provides a new class of deoxynojirimycin analogues, or
pharmaceutically acceptable salts thereof which can suitably be used for
the treatment of a disease selected from the group consisting of insulin
resistance, Gauger disease, inflammatory diseases, hyperpigmentation
and/or inflammatory skin conditions, overweight and obesity, lysosomal
storage disorders, fungal diseases, melanoma and other tumors, and
microbacterial infections. The invention further provides a
pharmaceutical composition comprising said deoxynojirimycon analogue, or
pharmaceutically acceptable salt thereof, and a pharmaceutically
acceptable carrier.